Literature DB >> 22858908

Lentiviral marking of patient-derived acute lymphoblastic leukaemic cells allows in vivo tracking of disease progression.

S Bomken, L Buechler, K Rehe, F Ponthan, A Elder, H Blair, C M Bacon, J Vormoor, O Heidenreich.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22858908      PMCID： PMC3836222          DOI： 10.1038/leu.2012.206

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  12 in total

1.  Detection and direct genomic sequencing of multiple rare unknown flanking DNA in highly complex samples.

Authors:  M Schmidt; G Hoffmann; M Wissler; N Lemke; A Müssig; H Glimm; D A Williams; S Ragg; C U Hesemann; C von Kalle
Journal:  Hum Gene Ther       Date:  2001-05-01       Impact factor: 5.695

2.  Retroviral insertion site analysis in dominant haematopoietic clones.

Authors:  Olga S Kustikova; Ute Modlich; Boris Fehse
Journal:  Methods Mol Biol       Date:  2009

3.  Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia.

Authors:  Dengli Hong; Rajeev Gupta; Philip Ancliff; Ann Atzberger; John Brown; Shamit Soneji; Joanne Green; Sue Colman; Wanda Piacibello; Veronica Buckle; Shinobu Tsuzuki; Mel Greaves; Tariq Enver
Journal:  Science       Date:  2008-01-18       Impact factor: 47.728

4.  The acute lymphoblastic leukaemia cell line SEM with t(4;11) chromosomal rearrangement is biphenotypic and responsive to interleukin-7.

Authors:  J Greil; M Gramatzki; R Burger; R Marschalek; M Peltner; U Trautmann; T E Hansen-Hagge; C R Bartram; G H Fey; K Stehr
Journal:  Br J Haematol       Date:  1994-02       Impact factor: 6.998

5.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice.

Authors:  T Lapidot; C Sirard; J Vormoor; B Murdoch; T Hoang; J Caceres-Cortes; M Minden; B Paterson; M A Caligiuri; J E Dick
Journal:  Nature       Date:  1994-02-17       Impact factor: 49.962

6.  Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity.

Authors:  Kristin J Hope; Liqing Jin; John E Dick
Journal:  Nat Immunol       Date:  2004-05-30       Impact factor: 25.606

7.  In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties.

Authors:  Christoph le Viseur; Marc Hotfilder; Simon Bomken; Kerrie Wilson; Silja Röttgers; André Schrauder; Annegret Rosemann; Julie Irving; Ronald W Stam; Leonard D Shultz; Jochen Harbott; Heribert Jürgens; Martin Schrappe; Rob Pieters; Josef Vormoor
Journal:  Cancer Cell       Date:  2008-07-08       Impact factor: 31.743

8.  CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL.

Authors:  Y Kong; S Yoshida; Y Saito; T Doi; Y Nagatoshi; M Fukata; N Saito; S M Yang; C Iwamoto; J Okamura; K Y Liu; X J Huang; D P Lu; L D Shultz; M Harada; F Ishikawa
Journal:  Leukemia       Date:  2008-04-17       Impact factor: 11.528

9.  High frequencies of leukemia stem cells in poor-outcome childhood precursor-B acute lymphoblastic leukemias.

Authors:  S Morisot; A S Wayne; O Bohana-Kashtan; I M Kaplan; C D Gocke; R Hildreth; M Stetler-Stevenson; R L Walker; S Davis; P S Meltzer; S J Wheelan; P Brown; R J Jones; L D Shultz; C I Civin
Journal:  Leukemia       Date:  2010-08-26       Impact factor: 11.528

10.  In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression.

Authors:  Corbin E Meacham; Emily E Ho; Esther Dubrovsky; Frank B Gertler; Michael T Hemann
Journal:  Nat Genet       Date:  2009-09-27       Impact factor: 38.330
View more
  17 in total

1.  Targeting cyclooxygenase by indomethacin decelerates progression of acute lymphoblastic leukemia in a xenograft model.

Authors:  Nina Richartz; Eva Duthil; Anthony Ford; Elin Hallan Naderi; Sampada Bhagwat; Karin M Gilljam; Marta Maria Burman; Ellen Ruud; Heidi Kiil Blomhoff; Seham Skah
Journal:  Blood Adv       Date:  2019-11-12

2.  Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL.

Authors:  Luke Jones; Jennifer Richmond; Kathryn Evans; Hernan Carol; Duohui Jing; Raushan T Kurmasheva; Catherine A Billups; Peter J Houghton; Malcolm A Smith; Richard B Lock
Journal:  Clin Cancer Res       Date:  2017-01-24       Impact factor: 12.531

3.  Long-term in vitro maintenance of clonal abundance and leukaemia-initiating potential in acute lymphoblastic leukaemia.

Authors:  D Pal; H J Blair; A Elder; K Dormon; K J Rennie; D J L Coleman; J Weiland; K S Rankin; A Filby; O Heidenreich; J Vormoor
Journal:  Leukemia       Date:  2016-05-25       Impact factor: 11.528

4.  An advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence imaging.

Authors:  Binje Vick; Maja Rothenberg; Nadine Sandhöfer; Michela Carlet; Cornelia Finkenzeller; Christina Krupka; Michaela Grunert; Andreas Trumpp; Selim Corbacioglu; Martin Ebinger; Maya C André; Wolfgang Hiddemann; Stephanie Schneider; Marion Subklewe; Klaus H Metzeler; Karsten Spiekermann; Irmela Jeremias
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

5.  Abundant and equipotent founder cells establish and maintain acute lymphoblastic leukaemia.

Authors:  A Elder; S Bomken; I Wilson; H J Blair; S Cockell; F Ponthan; K Dormon; D Pal; O Heidenreich; J Vormoor
Journal:  Leukemia       Date:  2017-05-10       Impact factor: 11.528

6.  Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma.

Authors:  Richard A Noble; Natalie Bell; Helen Blair; Arti Sikka; Huw Thomas; Nicole Phillips; Sirintra Nakjang; Satomi Miwa; Rachel Crossland; Vikki Rand; Despina Televantou; Anna Long; Hector C Keun; Chris M Bacon; Simon Bomken; Susan E Critchlow; Stephen R Wedge
Journal:  Haematologica       Date:  2017-04-06       Impact factor: 9.941

7.  Pontin is a critical regulator for AML1-ETO-induced leukemia.

Authors:  O Breig; S Bras; N Martinez Soria; D Osman; O Heidenreich; M Haenlin; L Waltzer
Journal:  Leukemia       Date:  2013-12-17       Impact factor: 11.528

8.  Development of a preclinical orthotopic xenograft model of ewing sarcoma and other human malignant bone disease using advanced in vivo imaging.

Authors:  Britta Vormoor; Henrike K Knizia; Michael A Batey; Gilberto S Almeida; Ian Wilson; Petra Dildey; Abhishek Sharma; Helen Blair; I Geoff Hide; Olaf Heidenreich; Josef Vormoor; Ross J Maxwell; Chris M Bacon
Journal:  PLoS One       Date:  2014-01-07       Impact factor: 3.240

9.  Dynamic clonal progression in xenografts of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21.

Authors:  Paul B Sinclair; Helen H Blair; Sarra L Ryan; Lars Buechler; Joanna Cheng; Jake Clayton; Rebecca Hanna; Shaun Hollern; Zoe Hawking; Matthew Bashton; Claire J Schwab; Lisa Jones; Lisa J Russell; Helen Marr; Peter Carey; Christina Halsey; Olaf Heidenreich; Anthony V Moorman; Christine J Harrison
Journal:  Haematologica       Date:  2018-02-15       Impact factor: 9.941

10.  Differential expression of miR-17~92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia.

Authors:  M Scherr; A Elder; K Battmer; D Barzan; S Bomken; M Ricke-Hoch; A Schröder; L Venturini; H J Blair; J Vormoor; O Ottmann; A Ganser; A Pich; D Hilfiker-Kleiner; O Heidenreich; M Eder
Journal:  Leukemia       Date:  2013-11-27       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.